|Articles|November 9, 2021
- Pharmaceutical Executive-11-01-2021
- Volume 41
- Issue 11
Pharmaceutical Executive, November 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 4 years ago
In It For the Long-Haul: Planning for the Future of COVID-19almost 4 years ago
Turning the Corner: A New Era of Pharma Sales Comes Into Viewalmost 4 years ago
An Industry Under Attack: Pharma Revisits Cybersecurity During COVID-19almost 4 years ago
The New COVID Workforce: Keeping Pharma Strong Through Adversityalmost 4 years ago
Crafting Curesalmost 4 years ago
Could 2022 Prove to Be Better Year for Biotech Companies?almost 4 years ago
COVID and the Data Talent Turnaboutalmost 4 years ago
Talent Pipelines Can Position Companies for Greater Hiring Successalmost 4 years ago
EU MEPs Arrive At Crossroads in Cancer Strategyalmost 4 years ago
Pharm Exec at 40 (2015-2018)Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Johnson and Johnson Reveals Plan to Separate Orthopaedics Business
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
4
Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda
5
